• Something wrong with this record ?

Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout

O. Hurba, A. Mancikova, V. Krylov, M. Pavlikova, K. Pavelka, B. Stibůrková,

. 2014 ; 9 (9) : e107902.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15022993

Grant support
NT11322 MZ0 CEP Register

OBJECTIVE: Using European descent Czech populations, we performed a study of SLC2A9 and SLC22A12 genes previously identified as being associated with serum uric acid concentrations and gout. This is the first study of the impact of non-synonymous allelic variants on the function of GLUT9 except for patients suffering from renal hypouricemia type 2. METHODS: The cohort consisted of 250 individuals (150 controls, 54 nonspecific hyperuricemics and 46 primary gout and/or hyperuricemia subjects). We analyzed 13 exons of SLC2A9 (GLUT9 variant 1 and GLUT9 variant 2) and 10 exons of SLC22A12 by PCR amplification and sequenced directly. Allelic variants were prepared and their urate uptake and subcellular localization were studied by Xenopus oocytes expression system. The functional studies were analyzed using the non-parametric Wilcoxon and Kruskall-Wallis tests; the association study used the Fisher exact test and linear regression approach. RESULTS: We identified a total of 52 sequence variants (12 unpublished). Eight non-synonymous allelic variants were found only in SLC2A9: rs6820230, rs2276961, rs144196049, rs112404957, rs73225891, rs16890979, rs3733591 and rs2280205. None of these variants showed any significant difference in the expression of GLUT9 and in urate transport. In the association study, eight variants showed a possible association with hyperuricemia. However, seven of these were in introns and the one exon located variant, rs7932775, did not show a statistically significant association with serum uric acid concentration. CONCLUSION: Our results did not confirm any effect of SLC22A12 and SLC2A9 variants on serum uric acid concentration. Our complex approach using association analysis together with functional and immunohistochemical characterization of non-synonymous allelic variants did not show any influence on expression, subcellular localization and urate uptake of GLUT9.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022993
003      
CZ-PrNML
005      
20170421095938.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0107902 $2 doi
035    __
$a (PubMed)25268603
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hurba, Olha $u Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
245    10
$a Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout / $c O. Hurba, A. Mancikova, V. Krylov, M. Pavlikova, K. Pavelka, B. Stibůrková,
520    9_
$a OBJECTIVE: Using European descent Czech populations, we performed a study of SLC2A9 and SLC22A12 genes previously identified as being associated with serum uric acid concentrations and gout. This is the first study of the impact of non-synonymous allelic variants on the function of GLUT9 except for patients suffering from renal hypouricemia type 2. METHODS: The cohort consisted of 250 individuals (150 controls, 54 nonspecific hyperuricemics and 46 primary gout and/or hyperuricemia subjects). We analyzed 13 exons of SLC2A9 (GLUT9 variant 1 and GLUT9 variant 2) and 10 exons of SLC22A12 by PCR amplification and sequenced directly. Allelic variants were prepared and their urate uptake and subcellular localization were studied by Xenopus oocytes expression system. The functional studies were analyzed using the non-parametric Wilcoxon and Kruskall-Wallis tests; the association study used the Fisher exact test and linear regression approach. RESULTS: We identified a total of 52 sequence variants (12 unpublished). Eight non-synonymous allelic variants were found only in SLC2A9: rs6820230, rs2276961, rs144196049, rs112404957, rs73225891, rs16890979, rs3733591 and rs2280205. None of these variants showed any significant difference in the expression of GLUT9 and in urate transport. In the association study, eight variants showed a possible association with hyperuricemia. However, seven of these were in introns and the one exon located variant, rs7932775, did not show a statistically significant association with serum uric acid concentration. CONCLUSION: Our results did not confirm any effect of SLC22A12 and SLC2A9 variants on serum uric acid concentration. Our complex approach using association analysis together with functional and immunohistochemical characterization of non-synonymous allelic variants did not show any influence on expression, subcellular localization and urate uptake of GLUT9.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alely $7 D000483
650    _2
$a zvířata $7 D000818
650    _2
$a biologický transport $7 D001692
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a běloši $7 D044465
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a exprese genu $7 D015870
650    _2
$a frekvence genu $7 D005787
650    _2
$a proteiny usnadňující transport glukosy $x genetika $7 D051246
650    _2
$a dna (nemoc) $x genetika $x patologie $7 D006073
650    _2
$a lidé $7 D006801
650    _2
$a hyperurikemie $x genetika $x patologie $7 D033461
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a přenašeče organických aniontů $x genetika $7 D027361
650    _2
$a proteiny přenášející organické kationty $x genetika $7 D027701
650    12
$a jednonukleotidový polymorfismus $7 D020641
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mančíková, Andrea $u Charles University in Prague, Faculty of Science, Department of Cell Biology, Prague, Czech Republic. $7 xx0279626
700    1_
$a Krylov, Vladimír $u Charles University in Prague, Faculty of Science, Department of Cell Biology, Prague, Czech Republic. $7 xx0128644
700    1_
$a Pavlíková, Markéta, $u Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. $d 1975- $7 xx0093283
700    1_
$a Pavelka, Karel, $u Institute of Rheumatology, Prague, Czech Republic. $d 1954- $7 jn99240000847
700    1_
$a Stibůrková, Blanka, $u Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic; Institute of Rheumatology, Prague, Czech Republic. $d 1970- $7 xx0056517
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 9 (2014), s. e107902
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25268603 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20170421100250 $b ABA008
999    __
$a ok $b bmc $g 1083332 $s 905986
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 9 $d e107902 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT11322 $p MZ0
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options